Filtered By:
Specialty: Drugs & Pharmacology
Condition: Parkinson's Disease
This page shows you your search results in order of date.
Order by Relevance | Date
Total 87 results found since Jan 2013.
Dopaminergic neuroprotective effects of inosine in MPTP-induced parkinsonian mice via brain-derived neurotrophic factor upregulation
Neuropharmacology. 2023 Jul 6:109652. doi: 10.1016/j.neuropharm.2023.109652. Online ahead of print.ABSTRACTParkinson's disease (PD) is the second most common neurodegenerative disease. However, no curative or modifying therapy is known. Inosine is a purine nucleoside that increases brain-derived neurotrophic factor (BDNF) expression in the brain through adenosine receptors. Herein, we investigated the neuroprotective effects of inosine and elucidated the mechanisms underlying its pharmacological action. Inosine rescued SH-SY5Y neuroblastoma cells from MPP+ injury in a dose-dependent manner. Inosine protection correlated wi...
Source: Neuropharmacology - July 8, 2023 Category: Drugs & Pharmacology Authors: Shristi Khanal Eugene Bok Jaekwang Kim Gyu Hwan Park Dong-Young Choi Source Type: research
Ablation of shank1 protects against 6-OHDA-induced cytotoxicity via PRDX3-mediated inhibition of ER stress in SN4741 cells
CONCLUSION: In summary, the present study has provided the first evidence that the knockdown of shank1 protects against 6-OHDA-induced ER stress and mitochondrial dysfunction through activating the PRDX3 pathway.PMID:36797610 | DOI:10.2174/1871527322666230216124156
Source: CNS and Neurological Disorders Drug Targets - February 16, 2023 Category: Drugs & Pharmacology Authors: Ye-Ping Xu Jing Zhang Xue Mei Yan Wu Wei Jiao Yu-Hai Wang Ai-Qin Zhang Source Type: research
Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy
Biochem Pharmacol. 2021 Dec 27:114899. doi: 10.1016/j.bcp.2021.114899. Online ahead of print.ABSTRACTThe accumulation of aggregated α-synuclein (α-syn) has been identified as the primary component of Lewy bodies that are the pathological hallmarks of Parkinson's disease (PD). Several preclinical studies have shown α-syn aggregation, and particularly the intermediates formed during the aggregation process to be toxic to cells. Current PD treatments only provide symptomatic relief, and α-syn serves as a promising target to develop a disease-modifying therapy for PD. Our previous studies have revealed that a small-molecul...
Source: Biochemical Pharmacology - December 30, 2021 Category: Drugs & Pharmacology Authors: H Cui S Norrbacka T T My öhänen Source Type: research
Protective effect of plastrum testudinis extract on dopaminergic neurons in a Parkinson's disease model through DNMT1 nuclear translocation and SNCA's methylation
In this study, we treated 6-hydroxydopamine (6-OHDA)-induced model rats and PC12 cells with PTE. The mechanism of action of PTE and ethyl stearate was investigated by western blotting, bisulfite sequencing PCR (BSP), real-time PCR, immunofluorescence and siRNA transfection. PTE effectively upregulated the TH expression and downregulated the alpha-synuclein expression in both the substantia nigra and the striatum of the midbrain in a PD model rat. The PC12 cell model showed that both PTE and its active monomer ethyl stearate significantly promoted TH expression and blocked alpha-synuclein, agreeing with the in vivo results....
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 21, 2021 Category: Drugs & Pharmacology Authors: Sen Ye Jun Zhong Jiapei Huang Lichun Chen Lan Yi Xican Li Jianping Lv Jifei Miao Hui Li Dongfeng Chen Caixia Li Source Type: research
NAPE-specific phospholipase D regulates LRRK2 association with neuronal membranes
Adv Pharmacol. 2021;90:217-238. doi: 10.1016/bs.apha.2020.09.003. Epub 2020 Oct 6.ABSTRACTN-acylphosphatidylethanolamines (NAPEs) are glycerophospholipid precursors for bioactive lipid amides and potential regulators of membrane function. They are hydrolyzed by NAPE-specific phospholipase D (NAPE-PLD) and have been implicated in neurodegenerative disorders such as Parkinson's disease. Here, we used siRNA-mediated silencing of NAPE-PLD in human SH-SY5Y cells and NAPE-PLD-/- mice to determine whether NAPEs influence the membrane association of LRRK2, a multifunctional protein kinase that is frequently mutated in persons with...
Source: Advances in Pharmacology - March 12, 2021 Category: Drugs & Pharmacology Authors: Francesca Palese Silvia Pontis Natalia Realini Daniele Piomelli Source Type: research
